| Ethical considerations of biomarker use in neurodegenerative diseases-A case study of Alzheimer's disease. | |
| | |
MedLine Citation:
|
PMID: 22137044 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
A major issue in current Alzheimer research presents in a growing dysbalance between a swiftly advancing biological marker and diagnostic research field (including advances in genetic research towards genetic profiling), key aspects of which have already found their way into newly proposed diagnostic criteria and international clinical dementia guidelines, and still rather limited and stagnating therapeutic and preventive options for physicians and patients worldwide. While Alzheimer's disease (AD) to date can be diagnosed with high accuracy years ahead of the late stage clinical syndromal dementia manifestation supported by biomarker guided detection of AD-characteristic pathophysiological features, there are currently no approved preventive or disease-modifying therapies available and the existing approved symptomatic therapy options provide only modest effect sizes in already demented patients without affecting the overall course and progression of the chronically progressive and complex brain disease. This unsatisfactory situation brings along a number of important ethical issues that need to be addressed. We outline some of the relevant ethical implications mainly related to the patient's best interest as well as to the patient's autonomy in the specific context of medical, psychological and social consequences of predicting AD using multi-modal biological markers. Consent, disclosure, or failure to disclose, information from genetic and predictive biomarker results raises significant ethical concerns among IRBs, regulators and advocacy groups. With the swift advances in ever earlier detection, diagnosis and classification in AD, a worldwide debate on ethical issues and consensus processes to reach a common ethical framework is warranted to safely and responsibly bring the best possible diagnostic measures as early as possible to patients and to the health care system. |
| | |
Authors:
|
David Prvulovic; Harald Hampel |
Related Documents
:
|
20198804 - Inequality as a cause of social murder. 12221504 - Bioethics and history. 21974664 - Introduction to focus issue on "randomness, structure, and causality: measures of compl... 22014284 - Ethical aspects of using gps for tracking people with dementia: recommendations for pra... 11437274 - The independence of practical ethics. 18210984 - Confessions of a bedside rationer: commentary on hurst and danis. |
Publication Detail:
|
Type: Journal Article Date: 2011-11-22 |
Journal Detail:
|
Title: Progress in neurobiology Volume: 95 ISSN: 1873-5118 ISO Abbreviation: Prog. Neurobiol. Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370121 Medline TA: Prog Neurobiol Country: England |
Other Details:
|
Languages: eng Pagination: 517-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011. Published by Elsevier Ltd. |
Affiliation:
|
Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University of Frankfurt, Heinrich-Hoffmann-Str. 10, 60528 Frankfurt, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glaucoma Progression Analysis Software Compared with Expert Consensus Opinion in the Detection of Vi...
Next Document: The future of Alzheimer's disease: The next 10 years.